Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition
Innovative strategies are necessary to maximize the clinical application of HIV neutralizing antibodies. To this end, bispecific constructs of human antibody F240, reactive with well-conserved gp41 epitope and antibody 14A8, reactive with the IgA receptor (CD89) on effector cells, were constructed....
Saved in:
Main Authors: | Xiaocong Yu, Mark Duval, Melissa Gawron, Marshall R. Posner, Lisa A. Cavacini |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2016/9425172 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
by: Katy Lloyd, et al.
Published: (2025-02-01) -
Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma
by: Carsten Müller-Tidow, et al.
Published: (2025-01-01) -
A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024-12-01) -
Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01) -
Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
by: Pauline Malinge, et al.
Published: (2024-12-01)